Skip to content

Prospective Assessment of Impact of Personalized Dosing of Low-dose Human Chorionic Gonadotropin (hCG) on in Vitro Fertilization (IVF) Outcomes

Prospective Assessment of Impact of Personalized Dosing of Low-dose Human Chorionic Gonadotropin (hCG) on in Vitro Fertilization (IVF) Outcomes

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04852029
Enrollment
12
Registered
2021-04-21
Start date
2021-08-16
Completion date
2021-12-31
Last updated
2022-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female

Brief summary

The purpose of the study is to determine the effect of tailoring dosage of low-dose hCG secondary to serum hCG levels during IVF ovarian stimulation on sustained implantation rates of preimplantation genetically tested euploid embryos.

Detailed description

The objective of this study is to conduct a double-blind prospective randomized control trial to determine if individualized hCG titration based on a patient's serum hCG level above or below the predetermined serum hCG level improves IVF outcomes, primarily sustained implantation rates. Patients who fall below the desired serum hCG threshold will be randomized to either maintaining their current dose of low dose hCG or being increased.

Interventions

Patients will either maintain the current dose of have an increased dose prescribed based on randomization

Sponsors

Reproductive Medicine Associates of New Jersey
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 46 Years
Healthy volunteers
No

Inclusion criteria

1. Patients whose physicians plan to prescribe low-dose hCG for ovarian stimulation 2. Age 18-46 3. Negative serum hCG prior to start of COH 4. BMI \>18 and \<35 5. Plan for ejaculated sperm use 6. Plan for PGT testing with euploid embryo transfer

Exclusion criteria

1. Administration of low-dose hCG during frozen embryo transfer cycle 2. Concomitant Menopur administration during ovarian stimulation or during frozen embryo transfer cycle 3. BMI \<18 or \>35 4. Age \<18 or \>46 5. Presence of hydrosalpinxes that communicate with the endometrial cavity 6. Diagnosis of endometrial insufficiency: prior cycle with maximal endometrial thickness ≤ 6mm, abnormal endometrial pattern (failure to attain a trilaminar appearance), and persistent endometrial fluid 7. Uncorrected uterine factor infertility (uterine anomaly, submucosal myomas, uterine septum) 8. Male partner with \<100,000 total motile spermatozoa per ejaculate (donor sperm is acceptable) 9. Use of surgical procedures to obtain sperm 10. Couples undergoing IVF for fertility preservation with no immediate plan for subsequent FET (embryo banking) 11. Personal history of repeated pregnancy loss (two or more unexplained clinical losses defined by presence of fetal heartbeat) 12. Declination of PGT testing

Design outcomes

Primary

MeasureTime frameDescription
sustained implantation rate8 weeks gestational agepresence of fetal heart beat upon discharge

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026